Changes in Hong Kong stocks | Yinnuo Pharmaceutical-B (02591) returned more than 13%, with a cumulative increase of 50% in the previous two weeks, and officially entered Hong Kong Stock Connect starting today

The Zhitong Finance App learned that Yinnuo Pharmaceutical-B (02591) rebounded more than 13%, and the cumulative increase in stock prices in the previous two weeks reached 50%. As of press release, it decreased by 13.64% to HK$38, with a turnover of HK$303.07 million.

According to the news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange issued an announcement stating that due to the implementation of component stock adjustments in the Hang Seng Composite Mid-Cap Index, the Hong Kong Stock Exchange list was adjusted in accordance with relevant regulations, and Yinnuo Pharmaceuticals will be transferred to the Hong Kong Stock Connect with effect from December 8, 2025. In addition, Yinnuo Pharmaceutical announced that the ultra-long-acting GLP-1 receptor agonist esupaglutide α (InnoLight®) independently developed by the company was officially included in the 2025 national medical insurance drug catalogue and will be implemented simultaneously with the new catalogue starting January 1, 2026.